Dr. Chan Siu Ki - Pathology
Specialist in Pathology
Highlights
- MCHK RegisteredVerified
- Specialist in PathologyBachelor of Medicine and Bachelor of Surgery (MBChB) · The Hong Kong College of Pathologists · Medical degree 2003
- InsuranceBeing compiled｜See details
About
Dr. Chan Siu Ki is a registered Pathology specialist in Hong Kong.
Education
Specialist in Pathology
- Bachelor of Medicine and Bachelor of Surgery (MBChB)Bachelor of Medicine and Bachelor of Surgery (MBChB)2003
Hong Kong Academy of Medicine fellowships
- FHKCPathFellow, The Hong Kong College of Pathologists
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Chan Siu Ki? Claim page and update insurance →
Hospital Affiliations
Referrals available to these hospitals
FAQ
Is Dr. Chan Siu Ki any good?
Dr. Chan Siu Ki is a registered Pathology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Chan Siu Ki do?
Dr. Chan Siu Ki practises in Pathology.
Are you Dr. Chan Siu Ki? Claim this page to update and manage.
ClaimResearch and publications
25 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.Pathology · 2021
- The significance of highlighting the oestrogen receptor low category in breast cancer.British journal of cancer · 2020
- Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors.Breast cancer research and treatment · 2020
- Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.Histopathology · 2020
- The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.The oncologist · 2020
- Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.Cancer immunology, immunotherapy : CII · 2020
- Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.Clinical breast cancer · 2020
- Predicting Outcome in Mammary Phyllodes Tumors: Relevance of Clinicopathological Features.Annals of surgical oncology · 2019
- Diagnostic upgrade of atypical ductal hyperplasia of the breast based on evaluation of histopathological features and calcification on core needle biopsy.Histopathology · 2019
- The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.Cancer research and treatment · 2019
- Expression of biomarkers in the AKT pathway correlates with malignancy and recurrence in phyllodes tumours of the breast.Histopathology · 2019
- GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.Breast cancer research and treatment · 2018
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer